Journal of the National Cancer Institute 1997-11-19
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Abstract
Background
The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer.
Methods
Eligible patients (n = 2306) were randomly assigned to one of three treatment groups following surgery. A total of 771 patients with follow-up data received tamoxifen alone; 767 received methotrexate, fluorouracil, and tamoxifen (MFT); and 768 received cyclophosphamide, methotrexate, fluorouracil, and tamoxifen (CMFT). The Kaplan-Meier method was used to estimate disease-free survival, distant disease-free survival, and survival. Reported P values are two-sided.
Results
Through 5 years of follow-up, chemotherapy plus tamoxifen resulted in significantly better disease-free survival than tamoxifen alone (90% for MFT versus 85% for tamoxifen [P = .01]; 89% for CMFT versus 85% for tamoxifen [P = .001]). A similar benefit was observed in both distant disease-free survival (92% for MFT versus 87% for tamoxifen [P = .008]; 91% for CMFT versus 87% for tamoxifen [P = .006]) and survival (97% for MFT versus 94% for tamoxifen [P = .05]; 96% for CMFT versus 94% for tamoxifen [P = .03]). Compared with tamoxifen alone, MFT and CMFT reduced the risk of ipsilateral breast tumor recurrence after lumpectomy and the risk of recurrence at other local, regional, and distant sites. Risk of treatment failure was reduced after both types of chemotherapy, regardless of tumor size, tumor estrogen or progesterone receptor level, or patient age; however, the reduction was greatest in patients aged 49 years or less. No subgroup of patients evaluated in this study failed to benefit from chemotherapy.
Conclusions
Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.
Related Questions
How would you approach adjuvant systemic therapy for a pT3N0(i+) HR+/HER2 negative breast cancer with an intermediate oncotype in a post-menopausal woman?
This is a great question that I ponder a lot. I've asked countless colleagues informally "what's the largest tumor you'll trust oncotype on"? The only true “prediction” data we have comes from the original B-20 trial, which included T3 tumors. Although the publication only breaks out tumor size as >...
What chemotherapy regimen do you prefer for postmenopausal women with T1 ER positive tumors with 1 positive LN?
For T1N1M0 ER positive tumors, I first do a Mammaprint. In MINDACT, Mammaprint low risk ER + N+ (up to three nodes) tumors had no improvement in 5 year DDFS (still about 94-95%) with the addition of chemotherapy to endocrine therapy.If the woman had a high risk Mammaprint, I would give AC x 4 follow...